Patent RadarTM← Home

Sample reports

Three real reports. Names changed.
The exact format your counsel receives.

Pharma, ophthalmics, and trademark monitoring. The format below is the exact shape of your dashboard and PDF export. About ninety seconds each.

High confidencePharma · USSample 01 of 03

Niravaribx 100 mg capsule

by Acuity Pharmaceuticals plc, reading on US11091459

Read score
84/100
Claim mapping4 elements
  • [1.a]
    92
  • [1.b]
    90
  • [1.c]
    58
  • [1.d]
    95

Rationale

Generic ANDA filing discloses an XRPD fingerprint and excipient profile that read directly on claim 1 limitations [1.a] through [1.d].

Top evidence

“Active ingredient is the tosylate monohydrate of compound A in a stable crystalline form, with XRPD peaks at 7.5°, 15.2°, and 22.7° (Cu Kα).”
fda.gov

Key findings

  • Owner: Tesaro / GSK
  • Claims hit: 4 of 12
  • All four limitations of claim 1 read on the ANDA's chemical fingerprint
  • XRPD pattern matches the patented Form I precisely
  • Same indication: maintenance treatment of recurrent epithelial ovarian cancer
Draft prepared by Patent Radar for legal review only.Run this on your patents →
High confidenceOphthalmics · EUSample 02 of 03

Lotenano-OD ophthalmic suspension

by Vista Ophthalmics SAS, reading on EP3194019

Read score
78/100
Claim mapping5 elements
  • [1.a]
    88
  • [1.b]
    81
  • [1.c]
    76
  • [4]
    64
  • [7]
    55

Rationale

EMA EPAR and sponsor press release disclose 200 nm chitosan-coated nanoparticle delivery, matching claim 1 elements [a] through [c].

Top evidence

“Active substance is dispersed as chitosan-coated nanoparticles of mean size 192 ± 18 nm, formulated as a sterile aqueous suspension.”
ema.europa.eu

Key findings

  • Owner: Bausch + Lomb
  • Claims hit: 3 of 8
  • Nanoparticle size (192 ± 18 nm) falls within the claimed 150 to 250 nm range
  • Chitosan coating layer disclosed in the EMA EPAR maps to limitation [b]
  • Formulation strength reads on dependent claims 4 and 7
Draft prepared by Patent Radar for legal review only.Run this on your patents →
Medium confidenceTrademark · EU + USSample 03 of 03

RadarSweep.app, beta release

by RadarSweep Inc., reading on EM 018234567

Read score
74/100
Claim mapping4 elements
  • [word]
    96
  • [logo]
    62
  • [class]
    92
  • [use]
    48

Rationale

App Store listing uses an identical word mark in class 9 and a confusingly similar figurative element. Likelihood of confusion is high under Sleekcraft factors.

Top evidence

“RadarSweep, your patent monitor in your pocket. Free for the first 30 days.”
apps.apple.com

Key findings

  • Owner: Drug Landscape Ltd
  • Claims hit: Identical word mark, similar logo, class 9
  • Identical wordmark in identical Nice class 9 (downloadable software)
  • Figurative element shares the centre-dot + sweep motif of the registered mark
  • Domain registered three months after the mark's filing went public
Draft prepared by Patent Radar for legal review only.Run this on your patents →

Want this report on your portfolio?

Book a 15-minute call with James. Custom quote in your inbox the same working day. No contract, no card.

Look up your patents →Talk to James